Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018 Mar 29;: Authors: Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D’Haens GR, SECURE study group Abstract BACKGROUND: Biological treatment of chronic inflammatory diseases has improved patient outcomes but increased health-care costs. Switching patients from originator infliximab to a biosimilar can reduce costs, but prospective data about pharmacokinetics and…

Read More

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):465-466 Authors: Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK PMID: 29462402 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29462402?dopt=Abstract

Read More

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):601-606 Authors: Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, Danese S Abstract Background: Infliximab (IFX) biosimilars CT-P13 and SB2 have comparable efficacy, safety, and immunogenicity to the originator Remicade (RMC). However, concerns about cross-switching patients between the 3 brands were raised in the absence of cross reactivity data between them. We aimed…

Read More

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2017 Dec 05;: Authors: Schmitz EMH, Boekema PJ, Straathof JWA, van Renswouw DC, Brunsveld L, Scharnhorst V, van de Poll MEC, Broeren MAC, Derijks LJJ Abstract BACKGROUND: Infliximab biosimilars have become available for treatment of inflammatory bowel disease (IBD). However, data showing long-term safety and effectiveness of biosimilars in IBD patients are limited. AIM: To study prospectively the switch from infliximab innovator to biosimilar in an IBD cohort…

Read More

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.

Related Articles Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Inflamm Bowel Dis. 2017 Aug 23;: Authors: Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL Abstract BACKGROUND: It has been previously shown that biosimilar infliximab CT-P13 is effective…

Read More

Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars.

Related Articles Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars. World J Gastroenterol. 2017 Jul 07;23(25):4473-4479 Authors: Hakizimana A, Ahmed I, Russell R, Wright M, Afzal NA Abstract In this article we discuss the challenges of delivering a high quality Transition care. A good understanding of the adolescent needs with good communication between Transition care physicians and the patient is essential for good continuity of care. Despite availability of several guidelines, one model doesn’t fit all and any transition service development should…

Read More
<< Go Back